Drug Trial Radar · NCT06959511
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Jul 22, 2025
Primary completion
Mar 1, 2028
Study completion Oct 1, 2030
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Exelixis
- First posted
- May 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To look at the effectiveness of zanzalintinib, followed by surgery, in treating advanced thyroid cancer. The safety of this treatment will also be studied.
Conditions
- Neoadjuvant Treatment
- Thyroid Cancer
Interventions
ZanzalintinibDrug
Given by po
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and adverse eventsTime frame: From baseline until completion of neoadjuvant therapy; an average of 6 months
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
University of Virginia
Charlottesville, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.